ZoeNCure Therapeutics
New Delhi, India
◆ Total Raised
$2.1M
◆ Stage
seed
◆ Location
New Delhi, India
◆ Founded
2024
◆ Team size
1-10
◆ Links
◆ About ZoeNCure Therapeutics
Delhi-based oncology biotechnology startup developing high-potency targeted cancer therapies, with focus on hard-to-treat liver and gastrointestinal cancers using antibody drug conjugates.
◆ What sets it apart
Develops targeted ADC-based cancer therapies for hard-to-treat liver and gastrointestinal cancers using a focused preclinical-to-clinic development strategy.
◆ Sectors
◆ Business
Modelhardware
CustomerHospitals, cancer specialists, and ultimately patients needing advanced oncology treatments
◆ Notable
- Closed an INR 20 crore seed financing round
- Funding was led by the Tyagi Family with angel co-investors
- Previously secured INR 2.5 crore pre-seed funding
- Advanced a lead ADC candidate toward first-in-human Phase 1 studies
- Signed a licensing agreement for antibody technology to develop next-generation ADCs in India
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does ZoeNCure Therapeutics do?
Delhi-based oncology biotechnology startup developing high-potency targeted cancer therapies, with focus on hard-to-treat liver and gastrointestinal cancers using antibody drug conjugates.
Where is ZoeNCure Therapeutics based?
ZoeNCure Therapeutics is based in New Delhi, India, founded in 2024.
How much has ZoeNCure Therapeutics raised?
ZoeNCure Therapeutics has raised $2.1M in tracked funding and is currently at the seed stage.
Who has invested in ZoeNCure Therapeutics?
Investors in ZoeNCure Therapeutics include Tyagi Family and angel co-investors.